Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2010-11, Vol.70 (2), p.119-128
• Main Authors: Rossi, Antonio, Garassino, Marina Chiara, Cinquini, Michela, Sburlati, Paola, Di Maio, Massimo, Farina, Gabriella, Gridelli, Cesare, Torri, Valter
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Carcinoma, Small Cell - diagnosis; Carcinoma, Small Cell - immunology; Carcinoma, Small Cell - pathology; Carcinoma, Small Cell - therapy; Chemotherapy; Consolidation therapy; Disease-Free Survival; Hematology, Oncology and Palliative Medicine; Humans; Immunotherapy; Interferons - therapeutic use; Lung Neoplasms - diagnosis; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Maintenance therapy; Medical sciences; Meta-analysis; Pneumology; Pulmonary/Respiratory; Randomized Controlled Trials as Topic; SCLC; Targeted therapy; Tumors; Tumors of the respiratory system and mediastinum
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2010.02.001

Abstract Objective To assess the role of maintenance or consolidation therapy in the treatment of small-cell lung cancer (SCLC), a meta-analysis of all published randomized clinical trials (RCTs) was performed in order to provide an overall meta-analysis and indirectly compare the effect of chemotherapy, interferons, and other biologic agents. Methods Electronic databases were searched for publication reporting of RCTs comparing maintenance or consolidation therapy versus placebo or follow-up alone until December 2008. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS), with their relative 95% confidence intervals (CI), were derived. In the calculation of HRs, the “no maintenance” arm served as a reference. The a priori value of p < 0.05 was chosen as significant level for statistical tests. Results Twenty-one RCTs, encompassing 3,688 patients, were eligible for the present analysis: 11 RCTs employing chemotherapy, 6 interferons (4 alpha and 2 gamma), and 4 other biological agents. Overall, no statistical advantage in OS (HR 0.93, 95% CI 0.87–1.00; p = 0.05) or in PFS (HR 0.98, 95% CI 0.91–1.06; p = 0.63) was reported for maintenance or consolidation therapy. Statistical evidence of different effects among the four types of therapy was detected for OS ( χ2 test for heterogeneity: 8.07 [3 df]; p = 0.04), but not for PFS. A statistically significant reduction of mortality was detected in those studies assessing the efficacy of chemotherapy (HR 0.89, 95% CI 0.81–0.98; p = 0.02) and of interferon-alpha (HR 0.78, 95% CI 0.64–0.96; p = 0.02). Conclusions The maintenance or the consolidation approach failed to improve the outcomes of SCLC. A survival advantage is suggested for maintenance chemotherapy and interferon-alpha, but its clinical impact needs to be confirmed by further studies.